Add Formweb to your mobile device
System Formulary Update
Nirsevimab (Beyfortus)
Situation:
Nirsevimab (Beyfortus) 50 mg/0.5 mL and 100 mg/1 mL intramuscular injections was approved for addition to the health system formulary at the System Pharmacy and Therapeutics Committee Meeting.
Background:
The following medication was reviewed: Nirsevimab (Beyfortus) 50 mg/0.5 mL and 100 mg/1 mL intramuscular injections
Assessment/Recommendations:
System P&T voted to add the following product from the UNC Health Medication Formulary with restrictions to outpatient/clinic use only and inpatient use if further restricted to patients who meet criteria for use:
- Nirsevimab (Beyfortus) 50 mg/0.5 mL intramuscular injection
- Nirsevimab (Beyfortus) 100 mg/1 mL intramuscular injection
Note: Stock of this formulary product may vary at individual entities
Formulary/Epic Changes will Go-Live on Tuesday, October 17, 2023